GENE ONLINE|News &
Opinion
Blog

2021-09-22| Special

ESMO21: Latest Clinical Studies Answer Central Questions in the Treatment of Leading Cancers

by Sahana Shankar
Share To
Pfizer’s Sutent (Sunitinib) is an approved anti-cancer adjuvant, which works as a tyrosine kinase inhibitor, approved for many cancers such as renal cell carcinoma. Dr. Eric Baudin, Chairman at Gustave Roussy, France, presented data from a clinical trial that reworked Sunitinib as an adrenal cancer drug.

FIRSTMAPP was designed as the first randomized, double-blind, academic Phase 2 trial to evaluate the effectiveness of Sunitinib to treat malignant pheochromocytoma and paraganglioma (mPGGL)- a very rare subtype of adrenal cancer. Compared against the placebo arm, Sunitinib performed well in progression free survival, overall survival, and partial responses, with manageable adverse events and an acceptable safety profile. 

Discussing the success of Sunitinib as a potential therapy for mPPGL, Dr. Rocio Garcia Carbonero, from the Gastrointestinal Tumor Unit at the Hospital Universitario Doce de Octubre in Madrid, mentioned the requirement of a robust treatment for this very rare cancer. She made a case for angiogenesis inhibitors as an effective intervention for mPGGL since most patients have germline mutations in the developmental pathway required for angiogenesis and hypoxia sensing.

GO Prime with only $1.49 now

LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!